H
Hefei Han Microbiology Technology
Microbiome-based live biotherapeutics for chronic diseases
About Hefei Han Microbiology Technology
Hefei Han Microbiology Technology Co., Ltd. (iBiome) is a biotechnology firm established in June 2021, specializing in the research and development of innovative therapies derived from the human gut microbiome. The company's core business revolves around creating live biotherapeutic products (LBPs) and microbiome-based drugs to address a range of conditions. It focuses on developing immune-modulatory treatments for metabolic diseases, tumors, inflammatory bowel disease, and autoimmune disorders by targeting the gut-brain axis.
The company was co-founded by Professor Zhu Shu and Tao Wanyin, who serves as the legal representative. The research and development team comprises scientists from prominent institutions such as Yale University, Harvard Medical School, and the University of Science and Technology of China. This team possesses a strong background in gut microbiology and immunology, underpinning the company's 'mechanism-oriented' drug development strategy. Hefei Han Microbiology Technology operates advanced R&D platforms that cover the entire process from strain screening and cultivation to efficacy evaluation and clinical trials.
Financially, the company has secured significant funding to advance its pipeline. In December 2021, it received an undisclosed amount in an angel round from CDG Capital. This was followed by a substantial Pre-A round in November 2023, raising over 100 million RMB, led by CICC Capital. A notable milestone was achieved in May 2025 when its IBOB001 enteric-coated capsule received clinical trial approval from the FDA for diabetes treatment.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 13.7/100
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
Growth signals
Latest recorded traffic for Hefei Han Microbiology Technology is 130 monthly website visits, down 76.4% over the last three months.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Hefei Han Microbiology Technology in its local ecosystem
The Hefei Han Microbiology Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hefei Han Microbiology Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hefei Han Microbiology Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.
